Dave Portnoy spurred a new generation of retail traders, but the Barstool Sports founder said Monday on CNBC's "Fast Money" he can't be responsible for the actions of others.'Barstooling It': The rise in retail trading activity is in part due to Portnoy branding himself as "Davey Day Trader." His newfound popularity in the trading universe is merely a function of "doing something the financial community hasn't seen before and making it fun," Portnoy said."We are 'Barstooling' it, we are making hype videos, we are getting behind it, we are live-streaming it," he said. "And I think a lot of the old-time guys just don't know what the hell is going on with us so they don't know what to make of us."See Also: Are Robinhood Retail Traders Fueling The Rally? It Depends Who You Ask'Clear What We Are': Portnoy makes it "clear what we are" and admits he has no "great...
Inovio Pharmaceuticals Inc (NASDAQ: INO) shareholders are suing the company in U.S. District Court alleging the vaccine maker misled investors by saying it came up with a coronavirus vaccine candidate in about three hours.When Inovio shared a developmental timeline for its DNA vaccine, codenamed INO-4700, in early March, the company said it designed the vaccine in three hours after the receiving the genetic sequence.That statement amounts to a deliberate misrepresentation to the public to inflate Inovio's stock price, the shareholders said in the lawsuit, which was filed Monday in the Eastern District of Pennsylvania. Inovio Shareholders Allege Stock Pumping: Ever since CEO J. Joseph Kim flaunted the "three-hour achievement" in a televised mid-February interview, the company has continued to release updates on the vaccine program in a bid to keep the stock on an upward trajectory, acccording to the lawsuit. The investors reiterated in the lawsuit that Inovio had not designed...
(Bloomberg) -- Chinese companies are ditching their U.S. listings at the fastest pace since 2015 as they grapple with rising tensions between Beijing and Washington.The latest is China’s biggest online classified firm 58.com Inc., which on Monday agreed to a buyout deal led by private equity firms Warburg Pincus and General Atlantic. An investor group backed by Chinese tech tycoon Pony Ma’s Tencent Holdings Ltd. said last week it will take Bitauto Holdings Ltd. private in a deal valuing the car-listing website at $1.1 billion.So far this year, U.S.-listed Chinese companies have announced four go-private deals with a combined value of $8.1 billion including debt, according to data compiled by Bloomberg. That’s up from zero during the same period last year. It’s also the highest value for any full year since 2015, when $29.8 billion of such buyouts were announced.The uptick comes as President Donald Trump weighs tighter scrutiny on Chinese...
Volkswagen will pay a 48% premium to buy out the minority shareholders of premium division Audi, Audi said on Tuesday. Volkswagen, which already holds 99.64% of Audi, announced the squeeze-out plans in February. "Volkswagen AG announced and specified that it has set the cash settlement to be paid to the minority shareholders in return for the transfer of their shares at 1,551.53 euros per AUDI AG share," the carmaker said....
Coronavirus vaccine maker Moderna Inc (NASDAQ: MRNA) is closing in on the final stages of its vaccine program and could have the efficacy data by Thanksgiving, paving the way for a potential Emergency Use Authorization approval by the FDA, Bloomberg reported, citing an interview with the company's CEO Stephane Bancel.What Happened: Moderna's coronavirus vaccine, codenamed mRNA-1273, is in Phase 2 testing and could yield efficacy data as early as Thanksgiving if everything goes right, Bancel told Bloomberg. The CEO also discussed about the possibility of the FDA according EUA at high risk."They might decide to give us emergency use approval for people at very high risk, while the agency more carefully reviews the data before granting approval for a broader population, " Bancel said.Moderna is measuring whether the vaccine prevents COVID-19 or potentially prevents infection, she said. Benzinga is covering every angle of how the coronavirus affects the financial world. For...
MARCY-L'ETOILE, France (Reuters) - France's president and top drugmaker announced plans on Tuesday to bolster domestic production of medicines as countries scramble to strengthen their healthcare industries to counter the coronavirus pandemic. Drugmaker Sanofi, which is working on two potential coronavirus vaccines, said it would invest 610 million euros ($679 million) at two French sites to turn them into a hub dedicated to research, development and production of vaccines. Speaking at the Marcy-L'Etoile facility, President Emmanuel Macron also pledged 200 million euros to help domestic research and manufacturing of medicines and said his government would announce plans on Thursday to bring back some drug production facilities to France....
